Objective: The authors evaluated attitudes toward complementary and alternative medicine (CAM) use in 2 populations of women receiving chemotherapy for epithelial ovarian cancer (EOC). Methods: Women with EOC currently being treated with chemotherapy at 2 tertiary cancer centers, in Canada and the United Kingdom, completed a self-administered questionnaire on attitudes and perceptions of CAM and types of CAM used within the previous month. Results: One hundred ninety-two patients (94 from Canada, 98 from United Kingdom) completed the questionnaire. Overall, 85 women (44%) were identified as CAM users. Complementary and alternative medicine use was more common among Canadian women (52%) compared with women from the United Kingdom (37%), P == 0.02. Participants used 71 different types of CAM, the majority (61 %) taking multiple CAM. The frequency of CAM use was the same in primary compared with recurrent disease. Eighty-nine percent of CAM users considered it important for their oncologist to be aware of CAM use. Canadian women, however, were less likely to infonn their physician (Canada: 50%; United Kingdom: 81 %), P = 0.02. Motivations for CAM use were the same in both populations including assist healing (60%), boost the immune system (57%), improve quality of life (48%), and relieve symptoms (45%). Thirteen percent thought CAM could cure cancer, whereas 17% thought it would prevent recurrence. Conclusions: Complementary and alternative medicine use is common in women receiving chemotherapy for EOC. Increasingly, interactions between CAM and prescribed medication are being identified. Oncologists should be aware and actively inquire about CAM use. Although patterns of CAM use differed, the motivation for starting CAM was similar, highlighting the need to address supportive care in all patients.
When all of these categories of CAM are considered 38(10 of the US general population are using some fonn of CAM, with 17.7% using nonvitamin, nonmineral natural products. 1 The use of CAM is even higher in cancer patients, with stl1dies reporting between 15% and 80% of patients using CAM ranging from herbal products to meditation. 25 There has been an increase in the rate of CAM use among cancer patients over the last decade.
ti , 7 Motivations for starting or continuing CAM following a cancer diagnosis include management of treatment-related adverse effects, prevention of cancer recurrence, and improving quality of life. s
There is evidence to support that CAM such as acupuncture and relaxation techniques can help patients manage pain, anxiety, and other mood disturbances associated with a cancer diagnosis. 5 However, there is little evidence for the efficacy of natural products as a treatment for cancer. Furthermore, there is the potential for significant herb-drug interactions that may affect efficacy and increase toxicity of conventional chemotherapy and other prescribed medications. 8 --1I There are few studies that specifically report on CAM use during chemotherapy. Defining and investigating patterns of CAM use in this population are therefore important.
There are limited data on the use of CAM in women with epithelial ovarian cancer (EOC).7,12.13 Ovarian cancer patients have many of the described clinical characteristics associated with CAM use, such as female, advanced stage disease at presentation, and a high rate of recurrence. 5. 14 It is likely that CAM use occurs during all stages of the cancer continuum; however, the prevalence of CAM use during chemotherapy for EOC is unknown.
The prevalence, attitudes, and types of eA M used may vary between patients from different geographic locations, with different types of cancer as well as during different stages of management of their cancer. 15--17 The aims of this study were to identify patterns of CAM usage in women during treatment with cytotoxic chemotherapy for EOC and to detennine their motivations, attitudes, and objectives for use. In addition, we compared CAM usage and attitl1des toward CAM between 2 EOC patient populations, one from Canada and one from the United Kingdom, as well as between CAM users and nonusers.
PATIENTS AND METHODS
This study was a cross-sectional observational study approved by the research ethics boards at the Princess Margaret Hospital, Toronto, Canada, and the Edinburgh Cancer Center, United Kingdom. Between May 2007 and August 2008, consecutive patients receiving chemotherapy for EOC in an ambulatory setting were approached to participate in this study. Patients were approached by a medical student or nurse and were assured that all responses would be anonymous and confidential. Patients were eligible if they were greater than 18 years of age, had a confirmed diagnosis of EOC, and were currently receiving cytotoxic chemotherapy for primary or recurrent disease. The participants must 588 have received at least 1 prior cycle of chemotherapy bef()re entering this study. Women were excluded if they were receiving experimental therapy, did not speak English, or could not participate in the infonned consent process.
All participants completed a self-administered questionnaire developed to obtain infonnation on types of CAM used within the preceding 4 weeks. Complementary and alternative medicine was defined as any natural products including dietary supplements, herbal and homeopathic remedies, and any nonconventional ingested phannaceutical. Regular multivitamins at the recommended daily dosing, including calcium and vitamin D, were not considered CAM. The questionnaire included 13 questions about beliefs and perceptions of patients using CAM during chemotherapy, derived from the literature and adapted from a self-administered questionnaire in women with breast cancer. 6 ,23.24 Participants responded to these questions using a Likert scale ranging from 1 (strongly disagree) to 5 (strongly agree).
The study patiicipants were also asked who they consulted before starting CAM, and whether they began taking CAM before or after the diagnosis of EOC. In addition, they were asked whether they had infonned their oncologist about CAM use and whether they felt it was important to do so. Clinical and demographic data were obtained from the patient and verified via the electronic patient record including chemotherapy regimen, primary or recurrent disease, comorbidities, and concurrent medications.
Statistics
Patient characteristics are presented descriptively as means, medians, or proportions. Clinical characteristics, demographic data, and type of CAM used were compared between the Canada and UK populations. Attitudes toward CAM use were compared between these 2 populations as well as between CAM users and nonusers in the total population. Comparisons between groups were perfonned using the independent-samples t test for continuous variables and the l test for categorical variables. P values were adjusted for multiple testing using Hommel's modified Bonferroni correction where applicable. All statistical tests are 2-sided, and the significance level was set at 0.05. All statistical analyses were performed with SAS (V9.1; SAS Institute, Cary, NC).
RESULTS
One hundred ninety-two women (total population) receiving cytotoxic chemotherapy for EOC in Canada (n = 94) and the United Kingdom (n = 98) participated in this study. Patient characteristics for both populations are shown in Table 1 .
Patterns of CAM Use Total Patient Population
In the total population, 85 women (44%) had used CAM in the preceding 4 weeks; these pru.iicipants are referred to as CAM users. Forty-five percent (32171 responders) started CAM after their diagnosis with EOC. Sixty-one percent (n = 52) of CAM users were taking 2 or more types of Medication 0 14 (15) 9 ( CAM, and 33% (n = 27) were taking 3 or more during chemotherapy. Patient characteristics were not found to differ significantly when comparing CAM users to nonusers. The median age of CAM users was 59 years, and for nonllsers, 61 years (P = 0.31). The patients had similar numbers of comorbidities (P = 0.31), and there was also a similar proportion of women taking prescription medication unrelated to their chemotherapy regimen during chemotherapy (80% [67/84 responders of CAM users] compared with 85% [89/105 responders of nonllsers]~ P = 0.36). Patients were just as likely to take CAM during primary treatment (46(%) as for recurrent disease (49%) (P = 0.6). Complementary and altemative medicine use was not dependent on the type of chemotherapy administered, P = 0.38).
Canada Versus the United Kingdom
Complementary and alternative medicine use was significantly more common in Canada with 52% (n = 49) of women using CAM compared with 37% (n = 36) in the United Kingdom ( 8 (22) 53 (56) 24 (53) 29 (59) 28 (78) 41 (44) 21 (47) 20 (41) 12 (35) 40 (42) 19 (42) 21 (43) 13 (38) 32 (34) 1 (38) 15 (31) 7 (21) 11 (12) 4 (9) 7 (14) 2 (6) 11 (12) 5 (11) 6 (12) 5 (14) 20 (21) 7 (16) 12 (24) 4 (11) 17 (18) 12 (27) 6 (12) 7 (20) 19 (20) 10 (22) In Canada, 2<1 (55%) of 5<1 women receiving carboplatinl pacIitaxel were CAM users compared with 20 (49%) of 41 receiving other chemotherapy. Similar proportional similarities were seen for primary compared with recunent disease, with 40% of women with primary disease and 33(Yc) with recurrent disease in the United Kingdom taking CAM compared with 50°;{) and 56%, respectively, in the Canadian population. There were 71 different types of CAM used by the women in this study. Sixty-three percent (n = 31) of Canadian women and 58% (n = 2 I) of British women were using 2 or more types of CAM (Table 1 , P = 0.2). Patterns of lIse varied between the 2 patient populations, with soy products being the most common in Canada (22%) followed by high-dose vitamin C (18%). The most common CAM in the United Kingdom were omega 3 and fish oil (25%) and evening primrose (19%) followed by vitamin C (17%). Products are listed in Table 2 . l) (25) Vitamin C J5(1R) 9 (lR) 6 (17) Soy products 14 (17) 11 (22) 3 (H)
Green tea
10 (12) 8 (16) 2 (6) Ginger l)(lI)
7 (14) 2 (6) Evening primrose 8 (9) I (2) 7 (19) Flax seed oil 7 (8) 4 (8) 3 (8) Essiac 6 (7) 5 (10)
3 (6) 1 (3) supplements Wobe-Mugos 3 (4)
Milk thistle 3 (4) 1 (2) 2 (6) LifeMel honey 3 (4) Sixty-ftlUr (75%) of all CAM users responded to the questions addressing their sources of infonnation before starting CAM. Twenty-two (34%) reported consulting more than I source before starting CAM. Before initiating CAM therapy, 41 (Vc, (n = 26) of CAM users reported consulting a physician (family practitioner or oncologist), and 31 % (n = 20) reported consulting with a friend or relative. Other sources included complementary medicine practitioners (27(y(" n = 17), a health food store employee ( 11 %, n = 7), and the Internet (13%, (n = 8), Three patients (5%) said they did not consult anybody.
Attitudes and Perceptions of CAM Use Total Patient Population
Seventy percent (50171 responders) of CAM users agreed with the statement that CAM was helpful (28143 responders in Canada [65%]; 22/28 responders in the United Kingdom [79%]). Complementary and alternative medicine users were more I ikely than non users to agree with positive statements and disagree with negative statements about CAM use. Although most CAM users found CAM to be helpful, only a minority thought they would directly impact their disease by curing cancer (13%), preventing disease spread (24%), or preventing a recurrence (17%) ( Table 3 ). The most commonly cited motivations for CAM use were as an adjunct to treatment, either to assist other treatments (40%), to boost the immune system (57%), or assist body's natural healing forces (60%). Other common motivations for CAM use during CAM Users, Nonusers, Adjusted n/responders (%) n/responders (%) P p* 11182 (13) Canada Versus the United Kingdom Table 4 compares attitudes toward CAM use between CAM users from Canada and the United Kingdom. These differences did not reach statistical significance. However, CAM users from the United Kingdom were less likely to believe that CAM may directly impact their disease by curing or preventing spread of cancer. Complementary and alternative medicine users from the United Kingdom were more likely to believe that CAM may not be perfectly safe, that they may have adverse effects, and that they could mitigate the efficacy of other therapies.
DISCUSSION
This is the first study to specifically report the use of natural products-a National Center for Complementary and Alternative Medicine subset of CAM-in women receiving cytotoxic chemotherapy for EOC, an area of increasing interest as data emerge suggesting the potential for interaction between CAM and prescribed medications. s -!! Our study demonstrates widespread use of CAM among women undergoing cytotoxic chemotherapy for EOC. These results are consistent with earlier studies suggesting CAM use in 40% to 50% of women at some time point during their cancer journey.7,!2,13 Almost half of all women with EOC are simultaneously using natural products during chemotherapy, with 61 % ingesting multiple CAM products, agents that could potentially impact on efficacy or toxicity profiles of chemotherapy and concurrent medication administered for oncological and other diagnoses.
Complementary and alternative medicine use in the general cancer population is associated with multiple clinical and demographic factors such as: advanced stage at diagnosis, poor prognosis, and recurrent disease. 14 . 1X The majority of women present with the International Federation of Gynecology and Obstetrics stage I1I1IV EOC, which is associated with a poor survival and may contribute to the high rate of CAM use in this population. Although interestingly, we did not see a difference in the proportion of women using CAM during chemotherapy for primary compared with recurrent disease (45% vs 44%). This was also evident in the proportion of women receiving carboplatin/paclitaxel, traditionally used either in the frontline treatment of EOC or in the early stages of progression in women with platinum sensitive recurrence, compared with other chemotherapy regimens. Breast and gynecologic cancer patients have a higher prevalence of CAM use compared with male cancer populations; 40% to 60% of breast cancer patients use natural products compared with 18% of prostate cancer patients. 5, 10 Higher levels of education and income are also associated with increased CAM use. Sociodemographic data were not specifically collected during this study as this has been extensively addressed elsewhere in the literature. D. 20.21 Complementary and alternative medicine use was significantly more prevalent among Canadian women (52%) compared with British patients (37%). Differences in clinical and demographic characteristics between these populations may partially account for this observed difference. The Canadian women were significantly younger than the women from the United Kingdom, which would suppOli a higher prevalence of CAM use. The United Kingdom had a higher proportion of patients with recurrent disease that in other population groups (notably breast cancer) would be associated with higher rates of CAM use. This does not appear to be a factor in this study as the same proportion of women using CAM was seen in both recurrent and primary disease.
Cancer patients from different countries of origin with different cultural backgrounds may make different decisions with regard to CAM therapy.!6 Patients from Asia may be more likely to use traditional Chinese herbal medicine, whereas North American patients us\: mind-body and manipulative-body-based interventions more fi·equently. I ~ A limitation of our study is that we did not capture accurate data on ethnicity, although previous studies have failed to show a significant relationship betwecn ethnicity and CAM use. U This study would have suffered similar limitations experienced by others. Specifically, it would have been dit:. ficult to detennine the influence of individual ethnicity versus the effect of regional culture on these women. Furthermore, because of language barriers, the survey was done only with English-speaking patients, which would have excluded, and biased, some ethnic influences. The differences seen between our populations may be due to a wider acceptance of CAM in North American culture, reflected in the perceptions and attitudes of Canadian compared with UK CAM users in our study. Alternatively, this may have been influenced by patients' willingness to disclose CAM usage within the survey. Given that UK patients indicated a greater likelihood to disclose CAM use to their oncologists (81!)i{) vs 50%). one might suspect the actual difference between CAM use in Canada and the United Kingdom may be even greater than that reported here. Complementary and alternative medicine users from Canada were more likely to believe CAM was beneficial and less likely to believe that CAM had adverse effects or interfered with the efficacy of traditional treatment.
Complementary and alternative medicine users rarely felt that CAM would directly impact their cancer by curing or preventing spread and recurrence. Rather, the most common motivation for CAM use was as a supportive measure, promoting healing and immunity, managing symptoms secondary to treatment, and overall improvement in quality of life. Interestingly, many of the natural products commonly used by women in this study are very popular for the treatment of menopausal symptoms. This may reflect an unmet need in women with EOC who often experience a surgeryor chemotherapy-induced menopause. Attitudes toward CAM use are consistent with reports in other cancer popuiations. 5 ,22 Most investigators report worse psychosocial distress and overall quality of life in CAM users compared with nonusers. 14 ,23 Other investigators have reported that although taking a single type of CAM is associated with less distress through a strong sense of control over their therapy, women taking multiple CAM have increased psychosocial distress. 22 Although it was beyond the scope of this study to assess overall quality of life, psychosocial distress, or symptom management, the high rate of CAM use as a supportive measure raises the question of whether women with EOC are being offered sufficient supportive care during chemotherapy.
Patients sought infonnatiol1 from a variety of sources about CAM before initiating treatment, the most common being a physician and least likely the Internet. Overall, 62% of CAM users discussed their current CAM use with their oncologist, which is consistent with earlier studies in other patient populations. 5, 15, 24 There are multiple reasons why patients do not tell oncologists about CAM use. These include failure of oncologists to ask and a perception that physicians are poorly infonned and may not approve of CAM use. 5 ,24 Studies have shown that cancer patients using CAM maintain a high level of trust in their physicians and would like guidance in making decisions regarding CAM. 24 • 25 In our study, up to 90% of patients felt it was imp0l1ant that their oncologist be aware of CAM use, indicating that patients want this dialogue with their treating physician. Initiating discussion about CAM with patients in an open manner as a routine part of care may promote better disclosure. This study shares the limitations of all questionnairebased surveys notably; the patient population are self-selected; patients may underreport CAM use; and questionnaire administration required an educational level and competency in English, which may exclude or deter some women from participation. 13 A significant prop011ion of women on chemotherapy for EOC are using CAM routinely. Some types of CAM have documented interactions with chemotherapy and other prescription medications that may impact their activity or metabolism and potentially increase toxicity or decrease efficacy.H-1O This is increasingly becoming an important area with databases and resources being developed to guide both patients and physicians. Given the high prevalence of CAM use in this patient population, it is important that physicians initiate and engage patients in discussions on CAM use. Further research on CAM is needed to obtain objective infonnation on efficacy, potential adverse effects, and interactions with conventional medications. Fmihermore, the expressed perceptions in this study about the role of CAM therapy reinforce how impoliant supportive care and patient empowernlent are to women with EOC. Oncologists need to be aware of these issues and actively assist patients in their decision making with regard to CAM.
